Atorvastatin calcium albumin nanoparticles as well as preparation and application thereof

By using BSA as a carrier to prepare atorvastatin calcium nanoparticles, the bioavailability and toxic side effects of atorvastatin calcium in the treatment of colorectal cancer were solved, and effective inhibition of colorectal cancer cells was achieved. The anti-tumor effect was further enhanced by combined use with sodium oxalinate.

CN118948806AActive Publication Date: 2024-11-15CHIMEDICAL UNIVERSITY

Patent Information

Application Number
CN202411034297.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

In the treatment of colorectal cancer, atorvastatin calcium has poor water solubility, low bioavailability, short plasma half-life and high toxic side effects, which limits its anti-tumor application.

Method used

Using bovine serum albumin (BSA) as a carrier, atorvastatin calcium albumin nanoparticles (AtvCa-BSA-NPs) were prepared by desolvent method to improve the bioavailability and anti-tumor activity of the drug, and with oxalinine Sodium is used in combination to enhance anti-tumor effects.

Benefits of technology

AtvCa-BSA-NPs significantly prolong the circulation time of the drug in the body, improve the inhibitory effect on colorectal cancer cells, and the use with sodium oxalinate further enhances the anti-tumor effect, providing a safe and effective anti-tumor nanometers preparation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention discloses atorvastatin calcium albumin nanoparticles as well as a preparation method and application thereof. The atorvastatin calcium albumin nanoparticles are prepared from atorvastatin calcium and serum albumin, and the mass ratio of the atorvastatin calcium to the serum albumin is (1: 3) to (1: 10). The preparation method comprises the following steps: weighing atorvastatin calcium, and adding absolute ethyl alcohol to fully dissolve the atorvastatin calcium to obtain an organic phase; weighing serum albumin, adding deionized water to fully dissolve the serum albumin, and adjusting the pH value of the solution with sodium hydroxide to obtain a water phase; under stirring, dropwise adding the organic phase into the water phase, adding a glutaraldehyde solution, continuously stirring and cross-linking, after cross-linking is finished, carrying out rotary evaporation to remove absolute ethyl alcohol, centrifuging the obtained solution by using a high-speed refrigerated centrifuge, and taking the lower layer precipitate as the atorvastatin calcium albumin nanoparticles. According to the present invention, the atorvastatin-entrapped albumin nanoparticles are prepared, such that the in-vivo circulation time of the atorvastatin calcium is prolonged, the bioavailability is improved, and particularly the antitumor activity of the atorvastatin calcium is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical preparations, and specifically relates to atorvastatin calcium albumin nanoparticles, a preparation method thereof, and applications thereof. Background Art

[0002] Atorvastatin calcium (AtvCa) is a white or off-white powder, slightly soluble in water and acetonitrile, slightly soluble in ethanol, and freely soluble in methanol.

[0003] AtvCa is a commonly used statin lipid-lowering drug in clinical practice. It has the function of lowering triglyceride and low-density lipoprotein cholesterol levels and increasing high-density lipoprotein cholesterol levels. It is mainly used clinically to treat hypercholesterolemia, atherosclerosis and coronary heart disease.

[0004] Colon cancer (COC) is a cancer formed by abnormal growth of colon cells. Due to the high pathological similarity with rectal cancer (RC), it is collectively referred to as colorectal cancer (CRC). According to the 2020 global cancer statistics, CRC has become the third most common cancer in the world, second only to breast cancer and lung cancer in incidence. In 2020, there were approximately 1.932 million new cases of CRC and approximately 935,000 deaths worldwide, accounting for as high as 48.4%. At present, the first-line drug treatment regimen is preferably chemotherapy combined with anti-epidermal growth factor receptor (EGFR) targeted therapy, or chemotherapy combined with anti-angiogenesis inhibitors. The main therapeutic drugs include fluorouracil, folinic acid, oxaliplatin, irinotecan, etc. These chemotherapy drugs have great killing power on tumors. While killing cancer cells, they also have obvious toxic side effects on normal tissue cells of the body, especially blood cells and lymphocytes that have important immune defense functions in the body. This greatly affects the patient's intraoperative adaptability and there is also a great risk of infection after surgery.

[0005] However, AtvCa has problems such as poor water solubility, low bioavailability, short plasma half-life, first-pass effect in the liver and toxic side effects, and high effective anti-tumor dose, which limit its further anti-tumor clinical application. These limitations can be overcome by combining the drug with an appropriate delivery carrier.

[0006] Bovine serum albumin (BSA), as a natural protein, has high biocompatibility and is a good drug delivery carrier. Studies have reported that BSA can actively target GP60 receptors on the surface of tumor cells. As a natural protein, BSA can achieve both active and passive targeting of tumor tissues. Its unique protein structure can load AtvCa, improve its poor solubility in water, which is not conducive to the formulation of the drug, and improve the anti-tumor efficacy.

[0007] Sodium oxamate (SO) is an inhibitor of lactate dehydrogenase (LDH). LDH is a glycolytic enzyme that mediates the bidirectional conversion between pyruvate and lactate and is one of the important metabolic enzymes regulating the energy metabolism of tumor cells. In a hypoxic environment, tumor cells have reduced mitochondrial oxidative phosphorylation levels, so more lactate is produced under the catalysis of LDH. Even when oxygen is sufficient to support mitochondrial oxidative phosphorylation, tumor cells tend to glycolyze. Tumor cells have sufficient nutrient supply, so excess energy is discharged in the form of lactate, which promotes rapid cell division. Therefore, inhibiting lactate produced by glycolysis is an effective solution to inhibit the development of cancer cells. In addition, patients with tumor resistance are often accompanied by dysfunction of the mismatch repair (MMR) system. Studies have shown that dysfunction of MMR will weaken the ability to detect DNA damage, and tumor cells will then be able to produce more mutations, improve adaptability, and develop resistance to anticancer drugs. SO can upregulate the expression of the MLH1 gene in the MMR system while inhibiting glycolysis, enhancing the anti-tumor ability of drugs and improving tumor resistance to drugs.

[0008] Currently, there is no report on preparing AtvCa into nanoparticles or administering AtvCa in combination with sodium oxamate for anti-tumor, especially anti-CRC. Summary of the invention

[0009] In order to solve the above-mentioned technical problems, the present invention prepares BSA nanoparticles (AtvCa-BSA-NPs) encapsulating AtvCa, aiming to prolong the in vivo circulation time of AtvCa and improve the bioavailability and anti-COC activity.

[0010] The technical solution adopted by the present invention is:

[0011] The invention discloses atorvastatin calcium albumin nanoparticles, which are composed of atorvastatin calcium and serum albumin, wherein the mass ratio of atorvastatin calcium to serum albumin is 1:3-1:10, preferably 1:4-1:5.

[0012] The serum albumin is one of bovine serum albumin, human serum albumin or ovalbumin.

[0013] The present invention also provides a method for preparing the atorvastatin calcium albumin nanoparticles, comprising the following steps:

[0014] 1) Weigh AtvCa, add an appropriate amount of anhydrous ethanol to fully dissolve it, and obtain an organic phase;

[0015] 2) Weigh serum albumin, add deionized water to fully dissolve it, and adjust the pH of the solution with sodium hydroxide to obtain an aqueous phase;

[0016] 3) Under stirring, the organic phase is dripped into the aqueous phase, and glutaraldehyde solution is added, and the cross-linking is continued under stirring. After the cross-linking is completed, the anhydrous ethanol is removed by rotary evaporation, and the obtained solution is centrifuged using a high-speed refrigerated centrifuge to take out the lower layer of precipitate as atorvastatin calcium albumin nanoparticles.

[0017] In the step 2), the pH is 7.5-9.0, preferably 8.0-9.0;

[0018] In step 2), the concentration of serum albumin is 5-20 mg / mL; preferably 10-15 mg / mL;

[0019] In the step 3), the volume ratio of the aqueous phase to the organic phase is 1:2-1:4;

[0020] In the step 3), the mass ratio of AtvCa in the aqueous phase to serum albumin in the organic phase is 10:1-3:1;

[0021] In the step 3), the concentration of the glutaraldehyde solution is 20%-25%;

[0022] In the step 3), the cross-linking time is 2-24 hours, preferably 4-24 hours.

[0023] Furthermore, the preparation method comprises the following steps:

[0024] 1) Weigh 8 mg of atorvastatin calcium AtvCa, add 12 mL of anhydrous ethanol to fully dissolve it, and obtain an organic phase;

[0025] 2) Weigh 40 mg of bovine serum albumin (BSA), add 4 mL of deionized water to fully dissolve it, and adjust the pH of the solution to 8.5 with sodium hydroxide to obtain an aqueous phase;

[0026] 3) After stirring the aqueous phase for 10 minutes, the organic phase was dropped into the aqueous phase under stirring, 10 μL of glutaraldehyde solution was added, and stirring was continued for cross-linking for 12 hours. After the cross-linking was completed, the anhydrous ethanol was removed by rotary evaporation at 45°C, and the obtained solution was centrifuged in a high-speed refrigerated centrifuge at 4°C and 12000 rpm for 60 minutes. The lower layer of precipitate was taken as atorvastatin calcium albumin nanoparticles AtvCa-BSA-NPs.

[0027] The invention discloses atorvastatin calcium albumin nanoparticle lyophilized powder. The preparation method comprises the following steps: preparing atorvastatin calcium albumin nanoparticles AtvCa-BSA-NPs into a solution, taking the AtvCa-BSA-NPs solution, adding a lyophilization protectant so that the concentration of the lyophilization protectant is 2-5% by mass volume percentage, stirring until the solution is evenly dispersed, placing the obtained product in a -80 DEG C refrigerator, and vacuum freeze-drying to obtain the AtvCa-BSA-NPs lyophilized powder.

[0028] Furthermore, the lyoprotectant is one or a combination of two or more of mannitol, trehalose or glucose.

[0029] The present invention also provides the use of atorvastatin calcium albumin nanoparticles or freeze-dried powder thereof in the preparation of anti-tumor drugs.

[0030] Furthermore, the tumor is colorectal cancer.

[0031] The beneficial effects of the present invention are:

[0032] The present invention successfully prepared AtvCa-BSA-NPs with sustained-release properties by a desolvation method. The results of in vitro experiments showed that AtvCa-BSA-NPs had an inhibitory effect on the proliferation of mouse COC CT26 cells and a variety of human COC cells, and had the ability to inhibit migration and induce cell apoptosis in mouse COCCT26 cells, and the ability to inhibit proliferation migration and induce apoptosis was stronger than that of AtvCa. The preparation is a safe and effective AtvCa nano preparation. The results of in vivo tumor-bearing mouse experiments showed that AtvCa-BSA-NPs could significantly inhibit tumor growth compared with AtvCa, and the combination of AtvCa-BSA-NPs and sodium oxamate could further enhance the in vivo anti-COC effect of AtvCa-BSA-NPs, which provides a new research idea for the further anti-COC application of AtvCa nanocarriers. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 This is the appearance of the freeze-dried powder prepared in Example 2 using different mixed protective agents.

[0034] Figure 2 The particle size diagram (A) and potential diagram (B) of AtvCa-BSA-NPs prepared in Example 3.

[0035] Figure 3 This is a transmission electron micrograph of AtvCa-BSA-NPs prepared in Example 3.

[0036] Figure 4 is the in vitro release curve of AtvCa and AtvCa-BSA-NPs;

[0037] The data are expressed as Mean±SD, n=3, ****P<0.0001.

[0038] Figure 5 is the effect of AtvCa and AtvCa-BSA-NPs on CT26 cells;

[0039] AB: Effects of AtvCa, AtvCa-BSA-NPs and Blank-BSA-NPs on CT26 cell viability and corresponding IC after 24 h of drug addition 50 ; CD: Effects of AtvCa, AtvCa-BSA-NPs and Blank-BSA-NPs on CT26 cell viability and corresponding IC after 48 h of drug addition 50 ; E: Effects of AtvCa, AtvCa-BSA-NPs and Blank-BSA-NPs on CT26 cell viability 72 hours after drug administration. Data are expressed as Mean±SD, n=3, *P<0.05, **P<0.01, ***P<0.001.

[0040] Figure 6 is the effect of AtvCa and AtvCa-BSA-NPs on HCT116 cells;

[0041] A: Effects of AtvCa, AtvCa-BSA-NPs and Blank-BSA-NPs on HCT116 cell viability 24 h after drug addition; BC: Effects of AtvCa, AtvCa-BSA-NPs and Blank-BSA-NPs on HCT116 cell viability 48 h after drug addition and the corresponding IC 50 ; DE: Effects of AtvCa, AtvCa-BSA-NPs and Blank-BSA-NPs on HCT116 cell viability and corresponding IC after 72 h of drug administration 50 Data are expressed as Mean±SD, n=3, *P<0.05, **P<0.01, ***P<0.001.

[0042] Figure 7 is the effect of AtvCa and AtvCa-BSA-NPs on HT29, SW480, and SW620;

[0043] A: Effects of AtvCa, AtvCa-BSA-NPs and Blank-BSA-NPs on HT29 cell viability 24 h after drug addition; BC: Effects of AtvCa, AtvCa-BSA-NPs and Blank-BSA-NPs on SW480 cell viability 24 h after drug addition and the corresponding IC 50; DE: Effects of AtvCa, AtvCa-BSA-NPs and Blank-BSA-NPs on SW620 cell viability and corresponding IC after 24 h of drug addition 50 Data are expressed as Mean±SD, n=3, *P<0.05, **P<0.01, ***P<0.001.

[0044] Figure 8 is the effect of AtvCa and AtvCa-BSA-NPs on HEK293 cells;

[0045] AC: Effects of AtvCa, AtvCa-BSA-NPs and Blank-BSA-NPs on HEK293 cell viability after 24h (A), 48h (B), and 72h (C) of drug administration. Data are expressed as Mean±SD, n=3, *P<0.05.

[0046] Fig. 9 is the effect of AtvCa and AtvCa-BSA-NPs on NIH3T3 cells;

[0047] AC: Effects of AtvCa, AtvCa-BSA-NPs and Blank-BSA-NPs on NIH3T3 cell viability after 24h (A), 48h (B), and 72h (C) of drug administration. Data are expressed as Mean±SD, n=3, **P<0.01.

[0048] Fig.10 is the 24 h scratch healing of CT26 by AtvCa and AtvCa-BSA-NPs;

[0049] Among them, A is the cell scratch state diagram observed by inverted microscope, and B is the relationship between scratch healing rate and concentration. Data are expressed as Mean±SD, n=3, *P<0.05, **P<0.01, ***P<0.001.

[0050] Fig.11 is the uptake of AtvCa-BSA-NPs by CT26 cells at 2h and 12h;

[0051] Among them, blue fluorescence represents DAPI-labeled cell nuclei, green fluorescence represents Cou-6-labeled AtvCa-BSA-NPs, and Merge represents the image after the DAPI and Cou-6 channels are superimposed. Scale bar: 100 μm.

[0052] Fig.12 is the apoptosis of CT26 cells induced by different concentrations of AtvCa and AtvCa-BSA-NPs;

[0053] Among them, AG: A represents the control group, BD represents the AtvCa administration concentrations of 10 μM (B) and 20 μM

[0054] (C) and 40μM (D) for 48h apoptosis flow cytometry, EG represents the apoptosis flow cytometry of AtvCa-BSA-NPs at a concentration of 10μM (E), 20μM (F), and 40μM (G) for 48h; HJ: the percentage of total apoptotic cells at a concentration of 10μM (H), 20μM (I), and 40μM (J) for 48h. Data are expressed as Mean±SD, n=3, *P<0.05, **P<0.01.

[0055] Fig.13 It is the tumor growth curve of tumor-bearing mice after different groups of drug treatment;

[0056] Data are expressed as Mean±SD, n=8, *P<0.05, ***P<0.001, ****P<0.0001.

[0057] Fig.14 It is the final tumor outcome of tumor-bearing mice after different groups of drug treatment;

[0058] Among them, A is the in vitro visual image of the tumor mass in each group, and B is the statistical graph of the final tumor mass weight in each group. Data are expressed as Mean±SD, n=8, *P<0.05, **P<0.01.

[0059] Fig.15 is the weight change of mice in each group;

[0060] The data are expressed as Mean±SD, n=8.

[0061] Fig.16 This is the H&E staining of the main tissues of CT26 tumor-bearing mice;

[0062] Wherein, magnification: ×400, scale: 50 μM.

[0063] Fig.17 is the serum ALT, AST, UREA and CREA levels of mice in each group;

[0064] Among them, A is ALT level, B is AST level, C is UREA level, and D is CREA level. Data are expressed as Mean±SD, n=3. DETAILED DESCRIPTION

[0065] In order to better understand the above-mentioned technical scheme, the technical scheme of the embodiments of the present application is described in detail below through the accompanying drawings and specific embodiments. It should be understood that the embodiments of the present application and the specific features in the embodiments are detailed descriptions of the technical scheme of the embodiments of the present application, rather than limitations on the technical scheme of the present application. In the absence of conflict, the embodiments of the present application and the technical features in the embodiments may be combined with each other.

[0066] As a new drug carrier, BSA has a good encapsulation effect on hydrophobic drugs and has little toxic side effects. There are many methods for preparing BSA nanoparticles, including desolvation method, emulsification method, spray method, self-assembly method, pH / thermosensitive gel method, Nab TM Technology, etc. The desolvation method is based on the introduction of hydrophobic drugs with organic solvents. The advantages are that it is simple and easy to obtain, the formed nanoparticles have a small particle size, and a suitable cross-linking agent is required. The emulsification method first needs to prepare an oil-in-water (W / O) emulsion under stirring, ultrasound, high-pressure homogenization and other conditions, and remove the organic solvent after solidification, but the obtained nanoparticles are not stable enough and often require the addition of emulsifiers, which affects the activity of the protein itself. In recent years, studies have used the water-in-oil-in-water (W / O / W) multiple emulsification method to obtain more stable albumin nanoparticles. Nab TM The technology is an improvement on the emulsification method and is suitable for many hydrophobic drugs. The free thiol groups of BSA are cross-linked to form disulfide bonds through high-pressure homogenization of the oil-water mixture, generating a cavity to encapsulate the drug inside. This cross-linking method is easy to operate and does not introduce organic solvents, but it has requirements for the protein binding rate of the drug. Preliminary experiments have found that this method is not effective for AtvCa encapsulation. The self-assembly method is a preparation method in which the BSA solution spontaneously forms nanoparticles through a reducing agent when the critical micelle concentration and the critical eutectic temperature are exceeded. The advantage is that the obtained particle size is small, but this method requires the use of a reducing agent, and the residue of the reducing agent may cause biological toxicity to the body. The pH / thermosensitive gel method requires precise control of pH and temperature. Based on the above analysis, the present invention determines the use of a desolvation method to prepare AtvCa-BSA-NPs. This method is suitable for a laboratory preparation environment, is controllable in operation, and the obtained nanoparticles are small in size.

[0067] The particle size and Zeta potential of AtvCa-BSA-NPs were analyzed using a laser particle size analyzer.

[0068] The microstructure of AtvCa-BSA-NPs was observed using transmission electron microscopy.

[0069] The encapsulation efficiency (EE) and drug loading (LC) of AtvCa-BSA-NPs were calculated according to the following formula (1) and formula (2):

[0070] EE=(m0-m1) / m0×100%………………(1)

[0071] LC=(m0-m1) / (m0+m BSA )×100%…………(2)

[0072] Wherein, m0 is the total dosage of AtvCa (in mg), m1 is the amount of unencapsulated AtvCa (in mg), and m BSA is the amount of BSA input (in mg).

[0073] Example 1 Preparation of Atorvastatin Calcium Albumin Nanoparticles

[0074] A kind of atorvastatin calcium albumin nanoparticles, the preparation method comprises the following steps.

[0075] 1) Weigh atorvastatin calcium AtvCa, add anhydrous ethanol to fully dissolve it, and obtain an organic phase;

[0076] 2) Weigh bovine serum albumin (BSA), add 4 mL of deionized water to fully dissolve it, and adjust the pH of the solution to 7.5-9.0 with sodium hydroxide to obtain an aqueous phase;

[0077] 3) After the aqueous phase is pre-stirred for 10 minutes, the organic phase is dropped into the aqueous phase under stirring, 5 to 20 μL of glutaraldehyde solution is added, and stirring is continued for cross-linking for 2 to 24 hours. After the cross-linking is completed, the anhydrous ethanol is removed by rotary evaporation at 45°C, and the resulting solution is centrifuged in a high-speed refrigerated centrifuge at 4°C and 12,000 rpm for 60 minutes, and the lower layer of precipitate is taken as atorvastatin calcium albumin nanoparticles AtvCa-BSA-NPs.

[0078] (I) Solution pH investigation

[0079] According to the above preparation method, atorvastatin calcium AtvCa8mg, ethanol volume 10mL, BSA dosage 40mg, cross-linking agent dosage 10μL and cross-linking time 12h were fixed unchanged, and the effects of BSA solution pH values ​​of 7.5, 8.0, 8.5, and 9.0 on particle size, PDI, encapsulation efficiency and drug loading were investigated. The results are shown in Table 1.

[0080] Table 1 Effect of solution pH on particle size, PDI, encapsulation efficiency and drug loading (n=3)

[0081]

[0082] The isoelectric point of BSA is 4.9. When the pH is higher than 7, the electrostatic repulsion between BSA molecules increases, which weakens the coagulation of BSA and makes it easier to form stable nanoparticles. As shown in Table 1, the pH value has a greater impact on the nanoparticle size and encapsulation efficiency within the range of 7.5-9.0. When the pH value is 7.5, white floccules begin to appear in the sample at the initial stage of stirring, and the floccules gradually gather to form precipitation. As the pH value increases to 8.0, 8.5 and 9.0, no precipitation occurs in the solution, and the particle size gradually decreases. When the pH value is 8.5, the encapsulation efficiency and drug loading reach the maximum. Therefore, considering the particle size and encapsulation efficiency, the pH value of the solution of the present invention is 8.0-9.0, preferably 8.5.

[0083] (II) Investigation of BSA dosage

[0084] According to the above preparation method, atorvastatin calcium AtvCa8mg, ethanol volume 12mL, solution pH 9.0, cross-linking agent dosage 10μL and cross-linking time 12h were fixed unchanged, and the changes in particle size, PDI, encapsulation efficiency and drug loading were investigated when 20, 40, 60, and 80mg of BSA (BSA concentration was 5-20mg / mL) were added to 4mL of deionized water. The results are shown in Table 2.

[0085] Table 2 Effect of BSA amount on particle size, PDI, encapsulation efficiency and drug loading (n=3)

[0086]

[0087] As can be seen from Table 2, the volume of the fixed BSA solution is 4 mL. As the amount of BSA increases, the particle size gradually increases, the encapsulation first increases and then decreases, and the drug loading gradually decreases. When the BSA dosage is 20 mg, the encapsulation rate is the lowest, and the sample begins to precipitate after being stored at 4°C for 1 hour. This may be due to the fact that the amount of BSA is too small and the unencapsulated drug precipitates. When the BSA dosage is 60 mg, the encapsulation rate is slightly higher than that of the nanoparticles with a BSA dosage of 40 mg, but the particle size is much larger than that of the nanoparticles with a BSA dosage of 40 mg. Therefore, considering the particle size, encapsulation rate and drug loading, the preferred amount of BSA in the present invention is 40 mg, at which time the mass ratio of AtvCa to BSA is 1:5, and the concentration of BSA is 10 mg / mL.

[0088] (III) Investigation on ethanol usage

[0089] According to the above preparation method, atorvastatin calcium AtvCa8mg, BSA dosage 40mg, volume 4mL, solution pH 9.0, cross-linking agent dosage 10μL and cross-linking time 12h were fixed, and the effects of ethanol dosage of 8, 10, 12, and 16mL on particle size, PDI, encapsulation efficiency and drug loading were investigated. The results are shown in Table 3.

[0090] Table 3 Effect of ethanol dosage on particle size, PDI, encapsulation efficiency and drug loading (n=3)

[0091]

[0092]

[0093] As shown in Table 3, with the increase of ethanol volume, the particle size and encapsulation efficiency gradually decreased, PDI reached the maximum when the ethanol dosage was 10 mL, and the overall change trend of drug loading was not large. When the ethanol dosage was increased to 12 mL and 16 mL, the particle size reached the minimum, but the decreasing trend slowed down, because with the increase of ethanol dosage, the encapsulation efficiency gradually decreased, and the amount of organic reagent should be as small as possible. Therefore, considering the influence of particle size and encapsulation efficiency, the present invention preferably has an ethanol dosage of 12 mL, at which time, the volume ratio of aqueous phase to organic phase is 1:3.

[0094] (IV) Investigation of dosing ratio

[0095] According to the above preparation method, the ethanol volume was fixed at 10 mL, the amount of BSA was 40 mg, the solution pH was 9.0, the amount of cross-linking agent was 10 μL and the cross-linking time was 10 h. The mass of AtvCa was 4 mg, 5 mg, 8 mg, 10 mg and 13.3 mg, that is, the mass ratio of BSA to AtvCa was 10:1, 8:1, 5:1, 4:1, 3:1, respectively. The effects on particle size, PDI, encapsulation efficiency and drug loading were investigated. The results are shown in Table 4.

[0096] Table 4 Effect of dosing ratio on particle size, PDI, encapsulation efficiency and drug loading (n=3)

[0097]

[0098] As shown in Table 4, when the dosage of AtvCa gradually increases, the particle size increases accordingly, and the drug loading gradually increases. There is no obvious trend in the change of encapsulation efficiency, but it reaches the maximum when the dosage ratio is 4:1, and the second is when the dosage ratio is 5:1. The particle size is relatively the smallest when the dosage is 10:1, 8:1 and 5:1, and the PDI is the lowest when the dosage is 5:1. Taking into account the effects of particle size, PDI, encapsulation efficiency and drug loading, the preferred dosage ratio of the present invention is 5:1.

[0099] (V) Investigation of the amount of cross-linking agent

[0100] Glutaraldehyde is a cross-linking agent with relatively large molecular flexibility, which can connect with the free amino groups of two BSA molecules to form two "arms" connected by Schiff bases, forming a stable and spatially flexible mesh cross-linking structure. Using glutaraldehyde to cross-link BSA can improve the encapsulation of drugs by nanoparticles. According to the above preparation method, atorvastatin calcium AtvCa8mg, ethanol volume 12mL, BSA dosage 40mg, solution pH 8.0 and cross-linking time 12h are fixed, and the effect of the amount of cross-linking agent glutaraldehyde added on particle size, PDI, encapsulation efficiency and drug loading is investigated, and the results are shown in Table 5.

[0101] Table 5 Effect of cross-linking agent dosage on particle size, PDI, encapsulation efficiency and drug loading (n=3)

[0102]

[0103] As shown in Table 5, with the increase of glutaraldehyde dosage, the particle size of the nanoparticles gradually decreases, which may be due to the cross-linking of more glutaraldehyde to form more compact skeleton structures. The encapsulation efficiency shows a trend of first increasing and then decreasing, reaching the maximum when the glutaraldehyde dosage is 10 μL, which may be due to the fact that less cross-linking agent makes the BSA network skeleton less formed, while more cross-linking agent makes the nanoparticle size greatly reduced, compressing the space for encapsulating AtvCa. Taking into account the biological toxicity of glutaraldehyde, as well as the influence of particle size and encapsulation efficiency, the preferred cross-linking agent dosage of the present invention is 10 μL.

[0104] (VI) Cross-linking time investigation

[0105] According to the above preparation method, atorvastatin calcium AtvCa8mg, ethanol volume 12mL, BSA dosage 40mg, solution pH 9.0 and cross-linking agent dosage 10μL were fixed unchanged, and the effect of glutaraldehyde cross-linking time of 2, 4, 8, 12, and 24h on particle size, PDI, encapsulation efficiency and drug loading was investigated. The results are shown in Table 6.

[0106] Table 6 Effect of cross-linking time on particle size, PDI, encapsulation efficiency and drug loading (n=3)

[0107]

[0108] As shown in Table 6, as the cross-linking time of glutaraldehyde increases, the particle size of the nanoparticles gradually decreases, the PDI first decreases and then increases, and the encapsulation efficiency reaches the maximum at 12 hours. Considering the biological toxicity of glutaraldehyde, as well as the influence of particle size and encapsulation efficiency, the preferred cross-linking time of the present invention is 12 hours.

[0109] Example 2 Preparation of Atorvastatin Calcium Albumin Nanoparticles Lyophilized Powder

[0110] A atorvastatin calcium albumin nanoparticle freeze-dried powder, the preparation method comprises the following steps:

[0111] 1) Weigh 8 mg of atorvastatin calcium AtvCa, add 12 mL of anhydrous ethanol to fully dissolve it, and obtain an organic phase;

[0112] 2) Weigh 40 mg of bovine serum albumin (BSA), add 4 mL of deionized water to fully dissolve it, and adjust the pH of the solution to 8.5 with sodium hydroxide to obtain an aqueous phase;

[0113] 3) After stirring the aqueous phase for 10 minutes, the organic phase was dropped into the aqueous phase under stirring, 10 μL of glutaraldehyde solution was added, and stirring was continued for cross-linking for 12 hours. After the cross-linking was completed, the anhydrous ethanol was removed by rotary evaporation at 45°C, and the obtained solution was centrifuged in a high-speed refrigerated centrifuge at 4°C and 12000 rpm for 60 minutes. The lower layer of precipitate was taken as atorvastatin calcium albumin nanoparticles AtvCa-BSA-NPs.

[0114] 4) The atorvastatin calcium albumin nanoparticles AtvCa-BSA-NPs were re-dissolved to obtain an AtvCa-BSA-NPs solution, a lyoprotectant was added so that the concentration of the lyoprotectant was 3% by mass volume, and the mixture was stirred until uniformly dispersed. The obtained product was placed in a -80°C refrigerator and vacuum freeze-dried to obtain AtvCa-BSA-NPs lyophilized powder.

[0115] (I) Selection of freeze-drying protective agent

[0116] According to the above preparation method, trehalose, mannitol and glucose were used as freeze-dried protective agents, and the properties of the obtained freeze-dried powder are shown in Table 7.

[0117] Table 7 Effect of lyophilization protective agent type on particle size, PDI, encapsulation efficiency and drug loading (n=3)

[0118]

[0119] As can be seen from Table 7, the particle size obtained by the mannitol group is the largest, and the freeze-dried powder particle size obtained by the glucose group is the smallest. In addition, although the particle size of the mannitol group is larger, the appearance is flat, the texture is uniform, and there is no collapse and agglomeration. The freeze-dried powders of the trehalose group and the glucose group all collapse to varying degrees. Considering the comprehensive particle size and appearance performance, and the need to obtain a freeze-dried powder that takes into account both the appearance and the particle size encapsulation rate index, the present invention preferably uses a mixture of mannitol and glucose as the freeze-dried protective agent.

[0120] (II) Selection of the ratio of mixed freeze-drying protective agent

[0121] According to the above preparation method, mannitol and glucose were used as freeze-dried protective agents, the total concentration of the mixed freeze-dried protective agent was 3% (w / v), and the mass ratio of mannitol to glucose was 3:7, 5:5 and 7:3 respectively. The properties and appearance of the freeze-dried powder obtained by using mannitol and glucose as freeze-dried protective agents in different mixing ratios are shown in Tables 8 and Figure 1 .

[0122] Table 8 Effect of freeze-drying protective agent type on particle size, PDI, encapsulation efficiency, and drug loading (n=3)

[0123]

[0124] As can be seen from Table 8, as the proportion of mannitol decreases, the particle size of the lyophilized powder after reconstitution becomes smaller, and reaches the minimum when the mixing ratio is 3:7. Figure 1 It can be seen that as the proportion of mannitol in the lyophilized protective agent increases, the collapse degree of the lyophilized powder gradually decreases, and the appearance is flat and uniform when the mannitol and glucose mixing ratio is 5:5 and 7:3. Taking into account the particle size and appearance, the present invention preferably uses a mannitol-glucose mixed lyophilized protective agent with a concentration of 3% (w / v) and a mannitol-glucose mass ratio of 5:5-3:7.

[0125] Example 3 Application of Atorvastatin Calcium Albumin Nanoparticles in Anti-colon Cancer (I) Preparation of Atorvastatin Calcium Albumin Nanoparticles

[0126] 1) Weigh 8 mg of atorvastatin calcium AtvCa, add 12 mL of anhydrous ethanol to fully dissolve it, and obtain an organic phase;

[0127] 2) Weigh 40 mg of bovine serum albumin (BSA), add 4 mL of deionized water to fully dissolve it, and adjust the pH of the solution to 8.5 with sodium hydroxide to obtain an aqueous phase;

[0128] 3) After stirring the aqueous phase for 10 min, the organic phase was dropped into the aqueous phase under stirring, 10 μL of glutaraldehyde solution was added, and stirring was continued for cross-linking for 12 h. After the cross-linking was completed, the anhydrous ethanol was removed by rotary evaporation at 45°C, and the obtained solution was centrifuged in a high-speed refrigerated centrifuge at 4°C and 12000 rpm for 60 min. The lower layer of precipitate was taken as atorvastatin calcium albumin nanoparticles (AtvCa-BSA-NPs).

[0129] (II) Characterization

[0130] 1. Particle size and potential determination

[0131] The particle size and Zeta potential of the prepared AtvCa-BSA-NPs are shown in Figure 2The particle size of AtvCa-BSA-NPs was 174.4±3.59nm, with uniform particle size distribution and good peak shape; the Zeta potential was -27.55±0.26mV, with good negative charge, indicating that the AtvCa-BSA-NPs system was stable.

[0132] 2. Morphological observation

[0133] Transmission electron microscopy observation of AtvCa-BSA-NPs showed Figure 3 As shown in the figure, AtvCa-BSA-NPs are clearly round with distinct edges and uniform spherical diameters, indicating that AtvCa-BSA-NPs were successfully prepared. There is a small amount of adhesion between the particles, which may be caused by the high sample concentration.

[0134] 3. In vitro release study of AtvCa-BSA-NPs

[0135] The in vitro release results of AtvCa and AtvCa-BSA-NPs were as follows Figure 4 . AtvCa-BSA-NPs released rapidly within 0-4h, and then the drug release rate slowed down, with the cumulative release reaching a maximum of 78.21±1.50% in 24h. AtvCa was released suddenly within 0-18h, with the cumulative release reaching 94.77±3.45% at 12h and 96.14±2.04% at 18h, and was completely released at 24h. By comparing the release curves of AtvCa and AtvCa-BSA-NPs, it can be seen that AtvCa-BSA-NPs slowed down the release rate of AtvCa, indicating that it has good sustained-release properties.

[0136] (III) Anti-colon cancer effect of AtvCa-BSA-NPs in vitro

[0137] Experimental cells: Mouse COC cells CT26, mouse fibroblasts NIH3T3, human embryonic kidney cells HEK293, and human COC cells HCT116, HT29, SW480, and SW620 were all from the cell bank of the Type Culture Collection Committee of the Chinese Academy of Sciences.

[0138] Cell culture: CT26, HCT116, HEK 293, HT29, NIH3T3, SW480 and SW620 cells were cultured in a constant temperature incubator at 37°C with 5% CO2. The complete medium used for cell culture contained 1% double antibody and 10% fetal bovine serum. CT26 used 1640 medium, HEK 293 and NIH3T3 used DMEM medium, SW480 and SW620 used L-15 medium, and HT29 and HCT116 used 5A medium.

[0139] Cell passaging: Take cells in logarithmic growth phase, discard the original culture medium, add appropriate amount of PBS to wash 3 times to remove metabolic waste and dead cells, add appropriate amount of trypsin solution containing EDTA, place in CO2 incubator for digestion, and after most cells are observed floating and moving in the form of sand grains under the microscope, add appropriate amount of complete culture medium to terminate digestion, and blow carefully. Place the cell suspension in a centrifuge, centrifuge at 1000rpm for 5 minutes, discard the supernatant, resuspend the cells with appropriate amount of culture medium, transfer to three culture dishes and place in CO2 incubator for culture.

[0140] Cell plating: Dilute the cells as needed and count them under a microscope to obtain a cell suspension of the target concentration. Taking a 96-well plate as an example, the cell suspension is plated at a density of 5×10 3 The cells were inoculated into 96-well plates and placed in an incubator until they were completely attached to the wall.

[0141] 1. Cytotoxicity test

[0142] 1.1) Cytotoxic effects of AtvCa-BSA-NPs and AtvCa on CT26 cells

[0143] The cytotoxicity of AtvCa-BSA-NPs, AtvCa and Blank-BSA-NPs on CT26 was determined by the CCK-8 method. CT26 cell plates were prepared and treated with different concentrations of AtvCa-BSA-NPs, AtvCa and Blank-BSA-NPs for 24h, 48h and 72h, and the control group was treated with fresh 1640 culture medium containing the same concentration of DMSO. Three parallel plates were performed for the AtvCa-BSA-NPs and AtvCa groups, respectively. After reaching the measurement time point, the old culture medium was discarded, and 100 μL of fresh culture medium containing 10% CCK-8 reagent was added to each well. After the culture plate was placed in an incubator and incubated for an appropriate time, it was placed in a microplate reader and the absorbance was measured at 450nm. The survival rate of cells treated with different concentrations of AtvCa-BSA-NPs, AtvCa and Blank-BSA-NPs and the overall IC 50 The results are as follows Figure 5 .

[0144] The cell growth survival rate was calculated according to the following formula:

[0145] CV=(A2-A0) / (A1-A0)×100%

[0146] Among them, V is the cell growth survival rate, A0 is the absorbance of the blank group, A1 is the absorbance of the control group, and A2 is the absorbance of the drug-treated group.

[0147] like Figure 5As shown in the figure, CCK-8 was used to detect the cytotoxic effects of AtvCa, AtvCa-BSA-NPs and Blank-BSA-NPs on CT26 cells at 24h, 48h and 72h. The results showed that Blank-BSA-NPs had no obvious toxicity to CT26, and each concentration group of AtvCa and AtvCa-BSA-NPs had different degrees of inhibitory effects on the proliferation of CT26 cells ( Figure 5 A, C, and E), and overall the inhibitory effect increases with the increase of drug concentration and time, and the inhibitory effect of AtvCa-BSA-NPs on cell survival is higher than that of the AtvCa group, which is significant at many concentrations. For example, when the drug concentration is 40μM and 60μM, the inhibition of AtvCa-BSA-NPs on CT26 cells is better than AtvCa at 24h and 48h (P<0.05), indicating that the sustained-release structure of AtvCa-BSA-NPs prolongs the action time of the encapsulated AtvCa and makes the inhibitory effect on cells more sustained. After 72h of drug action, the drug concentration of 20μM can cause great damage to the cells. When the AtvCa-BSA-NPs concentration is 40μM, the cell survival rate is only 1.66±0.51%. IC 50 The antitumor activity of AtvCa-BSA-NPs can be quantitatively evaluated, IC 50 The smaller the value, the stronger the anticancer activity. The IC 50 The IC values ​​of AtvCa-BSA-NPs on CT26 cells were 55.34 μM and 23.92 μM, respectively. 50 33.48μM and 19.49μM respectively ( Figure 5 B, D), IC of AtvCa-BSA-NPs 50 Compared with the raw material AtvCa, the IC values ​​of AtvCa and AtvCa-BSA-NPs were all lower. At 48h and 72h of administration, high concentrations of AtvCa and AtvCa-BSA-NPs had killed most of the cells, so there was no significant difference. At 72h of administration, a lower concentration of the drug could cause a significant decrease in cell viability, so the IC values ​​were not investigated. 50 The above results indicate that AtvCa-BSA-NPs have stronger cytotoxicity to CT26 and can significantly enhance the growth inhibition of CT26 by AtvCa.

[0148] 1.2) Cytotoxic effects of AtvCa-BSA-NPs and AtvCa on HCT116 cells

[0149] The cytotoxic effects of different concentrations of AtvCa-BSA-NPs, AtvCa and Blank-BSA-NPs on HCT116 cells at 24h, 48h and 72h were investigated by CCK-8 method, using the same method as 1.1. Figure 6 .

[0150] like Figure 6 As shown in the figure, AtvCa and AtvCa-BSA-NPs also have certain cytotoxicity to HCT116 at 24h, 48h, and 72h, while Blank-BSA-NPs has no obvious inhibitory effect on HCT116 ( Figure 6 A, B, and D). After 24 hours of administration, AtvCa and AtvCa-BSA-NPs had no inhibitory effect on HCT116, and the cell survival rate exceeded 90% at each administration concentration; after 48 hours of administration, the high-concentration group began to show toxicity to the cells, and AtvCa-BSA-NPs had better inhibition on cells than AtvCa at the administration concentrations of 60μM and 80μM; after 72 hours of administration, higher concentrations of AtvCa and AtvCa-BSA-NPs showed cytotoxicity, and AtvCa-BSA-NPs had stronger cytotoxicity at 100μM (P<0.05). At 24h and 48h of administration, the IC of AtvCa on HCT116 cells was 50 The IC values ​​of AtvCa-BSA-NPs on CT26 cells were 88.65 μM and 37.95 μM, respectively. 50 62.22μM and 36.58μM respectively ( Figure 6 (C, E), the results showed that AtvCa-BSA-NPs exhibited stronger HCT116 cytotoxicity than AtvCa, but were less sensitive than CT26.

[0151] 1.3) Cytotoxic effects of AtvCa-BSA-NPs and AtvCa on HT29, SW480, and SW620 cells

[0152] The cytotoxic effects of different concentrations of AtvCa-BSA-NPs, AtvCa and Blank-BSA-NPs on HT29, SW480 and SW620 cells for 24 h were investigated by CCK-8 method, using the same method as 1.1. The results are shown in Figure 7 .

[0153] like Figure 7 As shown in the figure, at 24 h, AtvCa and AtvCa-BSA-NPs had different degrees of inhibitory effects on HT29, SW480 and SW620, while Blank-BSA-NPs had no significant effect ( Figure 7A, B, and D). After 24 hours of administration, AtvCa-BSA-NPs began to show statistically significant inhibition on HT29 compared with AtvCa at a concentration of 60 μM (P<0.05), and the cell survival rate was 52.41±2.22% at 100 μM. After 24 hours of administration, AtvCa and AtvCa-BSA-NPs also had certain toxic effects on SW480 and SW620. At 100 μM, AtvCa-BSA-NPs had a stronger inhibitory effect on SW480 than AtvCa (P<0.05), and AtvCa-BSA-NPs had a stronger inhibitory effect on SW620 than AtvCa at 60 μM (P<0.05). However, when the administration concentration was increased to 80 μM and 100 μM, there was no significant difference in the effects of AtvCa and AtvCa-BSA-NPs (P>0.05). 24h IC of AtvCa-BSA-NPs on SW480 and SW620 50 The values ​​were 55.57 μM and 50.18 μM, respectively, which were less than the IC values ​​of AtvCa for SW480 and SW620. 50 76.34μM and 62.13μM ( Figure 7 (C, E), indicating that AtvCa-BSA-NPs have stronger inhibitory effects on SW480 and SW620 than AtvCa, and have a better effect on SW620.

[0154] 1.4) Cytotoxic effects of AtvCa-BSA-NPs and AtvCa on HEK293 cells

[0155] The cytotoxic effects of different concentrations of AtvCa-BSA-NPs, AtvCa and Blank-BSA-NPs on HEK293 cells at 24h, 48h and 72h were investigated by CCK-8 method to verify their safety. The method was the same as 1.1. Figure 8 .

[0156] like Figure 8 As shown in Figure 2, 24 h after administration, AtvCa and AtvCa-BSA-NPs had no significant inhibitory effect on HEK293 cells ( Figure 8 Middle A). After 48h of exposure to 10-40μM concentrations of AtvCa and AtvCa-BSA-NPs on HEK293 cells, the cell survival rates were all above 90%, while the cell survival rates of the experimental groups with higher concentrations began to decrease. At the maximum administration concentration of 100μM, the cell survival rates of the AtvCa and AtvCa-BSA-NPs groups dropped to 71.55±4.72% and 68.33±4.07%, respectively, with no statistical difference (P>0.05). At a concentration of 10μM, AtvCa and AtvCa-BSA-NPs showed significant differences in cell survival rates, but had no practical impact on the overall results ( Figure 8 B). After 72 hours of administration, there was no obvious regularity in the effects of different concentrations of AtvCa and AtvCa-BSA-NPs on cell viability. At the maximum administration concentration of 100 μM, the cell viability of AtvCa and AtvCa-BSA-NPs groups was the lowest, at 70.31±1.94% and 65.70±3.30% ( Figure 8 C). Blank-BSA-NPs have no obvious toxicity to HEK293. The experimental results show that AtvCa and AtvCa-BSA-NPs have no significant effect on the survival rate of HEK-293 cells at 10-100μM, and have slight toxicity when treated with high concentrations or for a long time, indicating that AtvCa-BSA-NPs will not cause significant toxicity to kidney cells while inhibiting the tumor cells mentioned above.

[0157] 1.5) Cytotoxic effects of AtvCa-BSA-NPs and AtvCa on NIH3T3 cells

[0158] Evaluation of whether the drug affects the proliferation of NIH3T3 cells is the basis for subsequent in vivo experiments and a necessary step to ensure in vivo safety. The CCK-8 method was used to investigate the cytotoxic effects of different concentrations of AtvCa-BSA-NPs, AtvCa and Blank-BSA-NPs on NIH3T3 cells at 24h, 48h and 72h, using the same method as 1.1). The results are shown in Fig. 9 .

[0159] like Fig. 9 As shown in the figure, Blank-BSA-NPs had no obvious toxicity to NIH3T3, while AtvCa and AtvCa-BSA-NPs had weak toxicity to NIH3T3. However, the toxicity increased with the increase of the administration concentration. After 24h of administration, the cell survival rates of AtvCa and AtvCa-BSA-NPs at the maximum concentration of 100μM were 81.36±3.22% and 78.94±3.06%, respectively. Fig. 9 There was no statistical difference (P>0.05). With the increase of administration time, the cytotoxicity of the low-concentration administration group did not change significantly, while the cytotoxicity of the high-concentration administration group increased slightly. After 48 hours of administration, the cell survival rates of AtvCa and AtvCa-BSA-NPs at a concentration of 100 μM were 71.97±3.33% and 64.19±6.75%, respectively ( Fig. 9 Middle B), 72h after administration, the cell viability of AtvCa and AtvCa-BSA-NPs at a concentration of 100 μM was 49.68±2.61% and 48.42±4.37%, respectively.

[0160] ( Fig. 9(C) Experimental results showed that different concentrations of AtvCa and AtvCa-BSA-NPs had low toxicity to NIH3T3 cells after 24h and 48h of administration, and had slight toxicity when treated for a long time and at high concentrations.

[0161] 2. Cell migration assay

[0162] Tumor cell migration is closely related to metastasis. The scratch test was used to observe the horizontal migration of CT26 cells after treatment with different concentrations of AtvCa-BSA-NPs and AtvCa for 24 h. 5 Cells were inoculated into 6-well plates, and a sterile 200μL pipette tip was used to press against the center line of the bottom of the well and scratch vertically, controlling the force to keep the scratch width equal. The detached cells were washed with PBS, and different concentrations of AtvCa-BSA-NPs and AtvCa were added to each well in the form of liquid replacement. One scratch field was selected from each well and marked. The concentration of the drug in the cell scratch experiment cannot have a toxic effect on the cells, so according to the cytotoxicity results of AtvCa-BSA-NPs and AtvCa on CT26, the dosage concentrations were determined to be 0, 5, 10, and 20μM, respectively. Three wells were tested in parallel for different dosage concentration groups of AtvCa-BSA-NPs and AtvCa, and photos were taken and recorded using an inverted microscope. The time point was recorded as 0h. After recording and taking pictures, the 6-well plate was placed in a cell culture incubator, taken out after 24h, and photographed and recorded using an inverted microscope. The results are shown in Fig.10 The experimental results were quantified using Image J to obtain the migration area, and the cell migration rate (MR) was calculated according to the following formula:

[0163] MR=(S0-S 24 ) / S0×100%

[0164] Where S0 is the scratch area at 0h, S 24 24h scratch area

[0165] like Fig.10 As shown, the degree of wound healing at different time points when AtvCa and AtvCa-BSA-NPs were administered at a concentration of 5 μM. There was no significant difference in the degree of wound healing of CT26 cells within 24 hours compared with the control group, and there was no significant difference between AtvCa and AtvCa-BSA-NPs ( Fig.10A, B). As the concentration of AtvCa and AtvCa-BSA-NPs increased to 10 and 20 μM, the wound healing rate showed a downward trend. When the concentration reached 10 μM, the wound healing rates of AtvCa and AtvCa-BSA-NPs within 24 hours were 37.98±4.20% and 26.65±3.75%, respectively. At this concentration, the AtvCa-BSA-NPs group had a stronger inhibition on cell migration than the control group, with a significant difference (P<0.01). When the drug concentration reached 20μM, the scratch healing rates of AtvCa and AtvCa-BSA-NPs within 24h were 34.20±4.87% and 21.14±2.60%, respectively. At this concentration, the AtvCa-BSA-NPs group had a significant difference compared with the control group (P<0.001), and when the drug concentration was 10μM and 20μM, the scratch healing rate of the AtvCa-BSA-NPs group was always lower than that of the AtvCa group (P<0.05). The experimental results showed that AtvCa and AtvCa-BSA-NPs could limit the migration ability of CT26, with a certain concentration dependence, and the encapsulation of AtvCa by AtvCa-BSA-NPs more effectively inhibited the horizontal migration of CT26 and weakened its horizontal diffusion and transfer ability.

[0166] 3. Cellular uptake assay

[0167] Preparation of Cou-6 labeled AtvCa-BSA-NPs: 8 mg AtvCa and 2.0 mg coumarin 6 (Cou 6) powder were accurately weighed and dissolved in ethanol, and then fully dissolved by ultrasonication as the organic phase to obtain coumarin 6 labeled AtvCa-BSA-NPs.

[0168] 3.1) Investigation of the uptake of AtvCa-BSA-NPs by CT26 cells

[0169] A laser confocal microscope was used for qualitative analysis to observe the uptake of AtvCa-BSA-NPs by CT26 cells. CT26 cells in the logarithmic growth phase were digested and counted at a concentration of 1.2×10 5The cells were diluted into confocal cell culture dishes at 100 μg / well and placed in a cell culture incubator. After attachment, AtvCa-BSA-NPs labeled with Cou 6 were added and diluted with culture medium to a Cou-6 concentration of 0.03 μg / mL. The cells were placed in a cell culture incubator and cultured for 2 h and 12 h, respectively. After the culture was completed, the culture medium was discarded, and the cells at the bottom of the dish were slowly washed 3 times with PBS. 200 μL of 4% paraformaldehyde fixative was added to each dish and fixed at room temperature for 20 min. After PBS was slowly washed again 3 times, an appropriate amount of DAPI was added to each dish to ensure that all cells were completely immersed in DAPI and incubated at room temperature for 5 min. The upper solution was then discarded, and the dish was washed 3 times with PBS, and finally 100 μL of PBS remained in each dish. The overall process was kept under light-proof conditions, and 3 groups were paralleled at each time point. Laser confocal microscopy was used to detect, take pictures and record the results. The results are as follows Fig.11 .

[0170] like Fig.11 As shown, in order to preliminarily investigate the uptake of AtvCa-BSA-NPs by CT26 cells, the present invention fluorescently labeled AtvCa-BSA-NPs, and the results showed that the cell nuclei at different time points showed obvious blue fluorescence, the cells were in good condition, the cytoplasm showed green fluorescence, and the fluorescence intensity increased with the increase of administration time, indicating that AtvCa-BSA-NPs can be taken up by CT26 cells, and the cumulative uptake increases with time.

[0171] 4. Cell apoptosis assay

[0172] 4.1) Comparison of the apoptotic effects of AtvCa and AtvCa-BSA-NPs on CT26 cells

[0173] Phosphatidylserine (PS) is mainly expressed on the inner side of healthy cell membranes. In the early stage of apoptosis, PS can be displaced from the inner side of the cell membrane to the surface of the cell membrane, and exposed to the extracellular environment. Annexin-V is a phospholipid binding protein that can specifically bind to PS. Annexin-V is labeled with Alexa Fluor 488 as a fluorescent probe, and the occurrence of early cell apoptosis can be detected using flow cytometry or fluorescence microscopy. Propidium iodide (PI) is a nucleic acid dye that cannot penetrate the cell membrane of normal cells, but because the cell membrane of cells in the middle and late stages of apoptosis and dead cells is damaged, PI can penetrate the cell membrane and enter the cell nucleus. By using Annexin-V Alexa-Fluor 488 and PI simultaneously on a flow cytometer, cells in the early and late stages of apoptosis and dead cells can be distinguished.

[0174] CT26 cells were cultured at 5 × 10 5The concentration of 100 μM / well was spread into a 6-well plate and placed in an incubator until the cells were evenly attached to the wall. The culture medium of each well of the experimental group was replaced with AtvCa and AtvCa-BSA-NPs with drug concentrations of 10, 20 and 40 μM, and the control group was added with the same drug-free culture medium and incubated in an incubator for 48 hours. After the incubation, the culture medium was discarded, carefully washed once with PBS, and 200 μL of EDTA-free trypsin was added to each well to digest the cells and incubated at room temperature. In order to avoid excessive trypsin digestion that damages the cell membrane and affects the apoptosis results, the digestion was stopped when the cells were observed to be slightly blown down, the cells were collected by centrifugation, and the cells were washed three times with PBS. 200 μL Binding Buffer was added to resuspend the cells, and 10 μL Annexin-VAlexa-Fluor 488 and 5 μL PI were added to each sample in the dark and mixed, and the staining was kept in the dark for 10 minutes, and 200 μL Binding Buffer was added to detect cell apoptosis on a flow cytometer. In the four-zone quadrant diagram of flow cytometry, the lower left quadrant is for live cells; the upper left quadrant is for cell debris and dead cells; the upper right quadrant is for necrotic cells and late apoptotic cells; the lower right quadrant is for early apoptotic cells, and the total apoptotic rate of each group was calculated. Fig.12 .

[0175] The results of CT26 cell apoptosis after 48h of Annexin-VAlexa-Fluor 488 and PI double staining are as follows Fig.12 As shown. When the drug concentration was 20μM and 40μM, the total apoptosis percentage of cells in the AtvCa and AtvCa-BSA-NPs groups was higher than that in the control group (P<0.05), and the apoptosis percentage increased with the increase of drug concentration. At 20μM and 40μM, the total apoptosis percentage of AtvCa and AtvCa-BSA-NPs reached 24.7±6.4% and 40.7±7.4%, 32.1±5.1% and 49.8±8.3%, respectively; when the drug concentration was 10μM, 20μM and 40μM, the total apoptosis percentage of cells in the AtvCa-BSA-NPs group was higher than that in the AtvCa group (P<0.05). The results showed that the encapsulation of AtvCa by AtvCa-BSA-NPs can significantly promote the apoptosis induction of CT26, showing a stronger anticancer effect.

[0176] In summary, the results of in vitro experiments showed that AtvCa-BSA-NPs had good toxic effects on COC cells CT26, HCT116, HT29, SW480 and SW620, and were more toxic than AtvCa cells. They were weakly toxic to human kidney cells HEK 293 and mouse fibroblasts NIH3T3. AtvCa-BSA-NPs inhibited the 24h horizontal migration of CT26 cells at concentrations of 10μM and 20μM, and the inhibitory effect was positively correlated with the administration concentration. AtvCa-BSA-NPs can be taken up by CT26 cells and aggregate in cells. Apoptosis experiments showed that inducing cell apoptosis may be the mechanism of AtvCa-BSA-NPs. AtvCa-BSA-NPs had a significantly higher percentage of apoptosis in CT26 cells than AtvCa at administration concentrations of 20μM and 40μM, and had a more significant pro-apoptotic effect.

[0177] (IV) In vivo anti-colon cancer effect of atorvastatin calcium albumin nanoparticles

[0178] Establishment of tumor-bearing mouse model: 100 μL CT26 cell suspension was subcutaneously injected into the lower right side of the back of each mouse. The growth of the tumor was observed every two days. The longer diameter and shorter diameter of the tumor were measured and recorded with a vernier caliper. The tumor volume (V) was calculated according to the following formula. When the overall tumor volume reached about 100 mm 3 Start dosing.

[0179] V=A×B 2 / 2

[0180] A is the longer diameter of the tumor (in mm), and B is the shorter diameter of the tumor (in mm).

[0181] 1. Evaluation of antitumor activity in tumor-bearing mice

[0182] The tumor-bearing mice were randomly divided into 6 groups according to the tumor volume, with 8 mice in each group, namely (1) Control (normal saline); (2) Blank-BSA-NPs; (3) AtvCa; (4) AtvCa-BSA-NPs; (5) sodium oxamate SO; (6) AtvCa-BSA-NPs+SO. The concentrations of AtvCa and AtvCa-BSA-NPs were 20 mg / kg, and the concentration of SO was 100 mg / kg. When the average tumor volume reached 100 mm 3 The drug was administered every other day. SO was injected intratumorally in solution, and the rest were injected into the tail vein. 3The mice were killed, the organs and tissues were separated, the tumors were removed, washed with saline and weighed. The anti-tumor effects of AtvCa and AtvCa-BSA-NPs and the effect of SO on the anti-tumor effect of AtvCa-BSA-NPs were evaluated using the tumor volume and final tumor weight of the mice as indicators. Fig.13 .

[0183] like Fig.13 As shown. On the 12th day of administration, the tumor volume of some mice in the Blank-BSA-NPs group was close to the ethically stipulated maximum tumor volume of 2000mm 3 Therefore, the experiment was terminated on the 12th day of administration. The tumor volume of the AtvCa group on the 12th day was 1434.41±538.90mm 3 , compared with 1557.73±321.88mm in the saline control group 3 and 1320.73±584.52 mm in Blank-BSA-NPs group 3 There was no statistical difference in tumor volume (P>0.05), indicating that 20 mg / kg of AtvCa API had no significant antitumor effect. This may be because AtvCa was partially decomposed in the blood after intravenous injection and was rapidly metabolized, resulting in less accumulation in the tumor site. The tumor volume of the AtvCa-BSA-NPs group on day 12 was 782.57±364.44mm 3 , which was lower than that of the saline control group (P<0.001) and the Blank-BSA-NPs group (P<0.05). The tumor volume was also smaller than that of the AtvCa group (P<0.05), indicating that the antitumor activity of AtvCa-BSA-NPs on CT26 was better than that of AtvCa. It is worth mentioning that the tumor volume of the AtvCa-BSA-NPs+SO group on day 12 was only 413.24±290.43mm 3 Compared with the AtvCa-BSA-NPs group, the tumor volume was further reduced (P<0.05), and there was also a statistically significant difference compared with the SO group (P<0.05). The tumor volume in the SO group was 1213.43±754.02mm 3 There was no statistical difference compared with the normal saline control group (P>0.05), indicating that 100 mg / kg SO alone had no obvious anti-tumor effect, but combined with AtvCa-BSA-NPs could further enhance the anti-tumor effect of AtvCa-BSA-NPs.

[0184] The mice and tumor tissues of each group were photographed and the tumor weights were statistically analyzed. Fig.14As shown. The tumor size of the AtvCa-BSA-NPs group was smaller than that of the AtvCa group. The tumor size of the AtvCa-BSA-NPs+SO group was smaller than that of the AtvCa-BSA-NPs group, while there was no significant difference between the SO group and the saline control group ( Fig.14 The average tumor mass weight of the AtvCa-BSA-NPs group was 0.61±0.36 g, which was lower than that of the control group (1.18±0.44 g) (P<0.05) and the Blank-BSA-NPs group (1.26±0.66 g) (P<0.05), and also lower than that of the AtvCa group (1.24±0.74 g) (P<0.05). The average tumor mass weight of the SO group was 1.32±0.67 g, which was not statistically different from the saline control group and the Blank-BSA-NPs group. The average tumor mass weight of the AtvCa-BSA-NPs+SO group was 0.30±0.21 g, which was lower than that of the SO group (P<0.01) and the AtvCa-BSA-NPs group (P<0.05) ( Fig.14 (middle B).

[0185] The results of tumor tissue diagram and final tumor weight showed that the AtvCa-BSA-NPs group had slower tumor growth and smaller final tumor volume than AtvCa, which could significantly improve the anti-tumor activity of AtvCa. In addition, the combined use of AtvCa-BSA-NPs and SO could further enhance the anti-tumor activity of AtvCa-BSA-NPs.

[0186] 2. Evaluation of toxic and side effects of delivery systems

[0187] 2.1) Mouse body weight

[0188] Before each administration, the health status of the mice was observed, the weight of all mice was measured and recorded, and a mouse weight-day curve was drawn. Fig.15 .

[0189] like Fig.15 As shown in the figure, the weight of mice in each group was measured and recorded before each administration. As time went on, the mice in each experimental group showed similar weight change trends: starting from the first administration, the weight of mice increased slowly, then remained stable, and continued to increase slowly after the 8th day. This shows that there was no abnormal decrease or fluctuation in the weight of mice in each group, and the overall change range was not much different, proving the safety of each group of drugs and administration methods.

[0190] 2.2) H&E staining of mouse tissue

[0191] The heart, liver, spleen, lung, kidney and tumor tissues of mice in each experimental group were stained by H&E staining to evaluate whether the tissue morphology had changed. First, paraffin tissue sections were made, and the mouse heart, liver, spleen, lung, and kidney were immersed and fixed in 4% paraformaldehyde fixative. The fixed tissues were rinsed with running water three times, and embedded in paraffin after dehydration with different concentrations of alcohol. After the paraffin was cooled, it was cut into uniform thick slices using a tissue slicer. The tissue sections were then dewaxed with xylene and ethanol, rinsed twice with double distilled water, and stained with hematoxylin dye. The staining was terminated by rinsing with running water to remove the dye, and then differentiated in 1% hydrochloric acid ethanol for a few seconds, rinsed with running water to return to blue, dehydrated in gradient alcohol and completely immersed in xylene for 20 minutes, and finally a drop of neutral gum was used to complete the final sealing. The stained tissue slices were placed under a microscope for observation and photography. The results are as follows Fig.16 .

[0192] H&E staining results Fig.16 After the treatment, no obvious inflammatory damage or lesions were found in the heart, liver, spleen, lung, and kidney of the mice in each experimental group, indicating that the drugs in each group and the intravenous injection and intratumoral injection methods had no toxic side effects on the organ tissues of mice, proving that AtvCa-BSA-NPs and AtvCa-BSA-NPs combined with SO have more effective anti-tumor effects.

[0193] 2.3) Mouse liver and kidney indicators

[0194] The liver and kidney function of mice was detected by serum biochemical index analysis to further evaluate the liver and kidney toxicity. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are important indicators of liver function. When liver cells are damaged, the ALT and AST levels in the blood increase. Creatinine (CREA) and urea (UREA) are important indicators of kidney function. When kidney function is impaired, the concentration of CREA and UREA excreted by kidney filtration in urine increases.

[0195] The mouse blood was collected and allowed to stand at room temperature for 15 minutes. The blood was centrifuged at 2000 rpm for 10 minutes. The supernatant was collected and centrifuged again under the same conditions. The residual blood cells in the supernatant were removed to obtain transparent colorless serum. The corresponding kits were used to detect the levels of ALT, AST, UREA and CREA in the serum. The results are shown in Figure 2. Fig.17 .

[0196] The results of ALT, AST, UREA and CREA test in mouse liver and kidney are as follows Fig.17As shown, the ALT, UREA and CREA indicators of each group were within the normal reference range, and there was no significant difference between the Blank-BSA-NPs group, AtvCa group, AtvCa-BSA-NPs group, SO group, and AtvCa-BSA-NPs+SO group and the control group. The AST index of the Blank-BSA-NPs group slightly exceeded the normal reference range, which was presumably caused by sampling error, while the AST indexes of the other groups were normal. The AST indexes of the AtvCa group, AtvCa-BSA-NPs group, SO group, and AtvCa-BSA-NPs+SO group were all within the normal reference range, and there was no significant difference compared with the control group. The results showed that AtvCa-BSA-NPs and AtvCa-BSA-NPs+SO had no obvious toxic side effects on the liver and kidneys of mice.

[0197] The present invention established a CT26 tumor-bearing mouse model, and used the tumor volume change trend and tumor weight as indicators to preliminarily evaluate the in vivo tumor inhibition effect of AtvCa, AtvCa-BSA-NPs, and the combination of AtvCa-BSA-NPs and SO. Compared with AtvCa, AtvCa-BSA-NPs has a significantly increased anti-tumor effect. The combined use of AtvCa-BSA-NPs and SO further enhances the inhibition of tumors. The safety of tail vein injection of AtvCa-BSA-NPs and intratumoral injection of SO was demonstrated by the weight change trend of mice, liver and kidney indicators, and H&E staining. It was demonstrated that the use of BSA as an AtvCa delivery carrier can prolong the in vivo action time of the drug and achieve a stronger tumor treatment effect in COC, while SO can further enhance the treatment effect, providing ideas and research basis for the further clinical application of AtvCa.

Claims

1. An atorvastatin calcium albumin nanoparticle, characterized in that: The invention is composed of atorvastatin calcium and serum albumin, wherein the mass ratio of atorvastatin calcium to serum albumin is 1:3-1:10, preferably 1:4-1:

5.

2. The atorvastatin calcium albumin nanoparticles according to claim 1, characterized in that The serum albumin is one of bovine serum albumin, human serum albumin or ovalbumin.

3. The atorvastatin calcium albumin nanoparticles according to claim 1 or 2, characterized in that: The atorvastatin calcium can be replaced by atorvastatin or its salt, and the salt is preferably potassium salt, sodium salt, magnesium salt, ammonium salt, iron salt, zinc salt, selenium salt, molybdenum salt, chromium salt, cobalt salt, manganese salt of atorvastatin.

4. The method for preparing atorvastatin calcium albumin nanoparticles according to any one of claims 1 to 3, comprising the following steps: 1) Weigh atorvastatin calcium, add appropriate amount of anhydrous ethanol to fully dissolve it, and obtain an organic phase; 2) Weigh serum albumin, add deionized water to fully dissolve it, and adjust the pH of the solution with sodium hydroxide to obtain an aqueous phase; 3) Under stirring, the organic phase is dripped into the aqueous phase, and glutaraldehyde solution is added, and the cross-linking is continued under stirring. After the cross-linking is completed, the anhydrous ethanol is removed by rotary evaporation, and the obtained solution is centrifuged using a high-speed refrigerated centrifuge to take out the lower layer of precipitate as atorvastatin calcium albumin nanoparticles.

5. The preparation method according to claim 4, characterized in that: In the step 2), the pH is 7.5-9.0, preferably 8.0-9.0; the concentration of serum albumin is 5-20 mg / mL; preferably 10-15 mg / mL; in the step 3), the volume ratio of the aqueous phase to the organic phase is 1:2-1:4; the mass ratio of AtvCa in the aqueous phase to serum albumin in the organic phase is: 10:1-3:

1.

6. The preparation method according to claim 3, characterized in that: The following steps are included. 1) Weigh 4-15 mg of atorvastatin calcium AtvCa, add 8-16 mL of anhydrous ethanol to fully dissolve it, and obtain an organic phase; 2) Weigh 20-80 mg of bovine serum albumin (BSA), add 3-5 mL of deionized water to fully dissolve it, and adjust the pH of the solution to 7.5-9.0 with sodium hydroxide to obtain an aqueous phase; 3) After the aqueous phase is pre-stirred for 10 to 15 minutes, the organic phase is dropped into the aqueous phase under stirring, 5 to 20 μL of glutaraldehyde solution is added, and stirring is continued for cross-linking for 2 to 24 hours. After the cross-linking is completed, the anhydrous ethanol is removed by rotary evaporation at 40 to 50° C. The resulting solution is centrifuged in a high-speed refrigerated centrifuge at 4° C., 12,000 rpm for 60 minutes, and the lower precipitate is taken as atorvastatin calcium albumin nanoparticles.

7. An atorvastatin calcium albumin nanoparticle freeze-dried powder, characterized in that: The atorvastatin calcium albumin nanoparticle freeze-dried powder is obtained by preparing the atorvastatin calcium albumin nanoparticles according to any one of claims 1 to 3 into a solution, adding a freeze-drying protective agent, and vacuum freeze-drying.

8. The atorvastatin calcium albumin nanoparticle freeze-dried powder according to claim 7, characterized in that: The lyoprotectant is one or a combination of two or more of mannitol, trehalose or glucose, preferably a combination of mannitol and glucose in a mass ratio of 3:7 to 7:

3.

9. Use of the atorvastatin calcium albumin nanoparticles according to any one of claims 1 to 3, or the atorvastatin calcium albumin nanoparticle freeze-dried powder according to claim 7 or 8, or a combination of atorvastatin calcium albumin nanoparticles and sodium oxamate in the preparation of a drug for treating cancer.

10. The use according to claim 9, characterized in that: The cancer is colorectal cancer.

Citation Information

Patent Citations

  • Preparation method of human serum albumin nano granules coated with oxaliplatin

    CN101708337A

  • Preparation method of protein nanoparticle for in vivo delivery of pharmacologically active agent

    CN102048695A

  • Atorvastatin calcium nano freeze-dried powder and preparation method thereof

    CN103110594A

  • Anti-tumor active drug loaded serum albumin nanoparticles and preparation therefor

    CN110898034A

Cited By

  • Simvastatin albumin nanoparticle and preparation and use thereof

    WO2026026697A1